Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016

Description: Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016

Summary

Our Medical Devices sector report, "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016" provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by our team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Dry Powder Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Dry Powder Inhaler Devices Overview
3 Products under Development
3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory
3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials
4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies
4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
5 Dry Powder Inhaler Devices Companies and Product Overview
5.1 Acorda Therapeutics, Inc. Company Overview
5.1.1 Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.2 Adamis Pharmaceuticals Corporation Company Overview
5.2.1 Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.3 Advent Pharmaceuticals Pty Ltd Company Overview
5.3.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.4 Aespira Ltd. Company Overview
5.4.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.5 AKELA Pharma Inc. (Inactive) Company Overview
5.5.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.6 Bayer HealthCare AG Company Overview
5.6.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
5.7 Bespak Europe Ltd. Company Overview
5.7.1 Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.8 GlaxoSmithKline Plc Company Overview
5.8.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Hovione FarmaCiencia SA Company Overview
5.9.1 Hovione FarmaCiencia SA Pipeline Products & Ongoing Clinical Trials Overview
5.10 MannKind Corporation Company Overview
5.10.1 MannKind Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.11 Nanotherapeutics, Inc. Company Overview
5.11.1 Nanotherapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.12 Nektar Therapeutics Company Overview
5.12.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
5.13 Novartis AG Company Overview
5.13.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
5.14 OPKO Health, Inc. Company Overview
5.14.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.15 Pharmaxis Limited Company Overview
5.15.1 Pharmaxis Limited Pipeline Products & Ongoing Clinical Trials Overview
5.16 Respira Therapeutics, Inc. Company Overview
5.16.1 Respira Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.17 Sandoz International GmbH Company Overview
5.17.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.18 Sheffield Hallam University Company Overview
5.18.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
5.19 Shin Nippon Biomedical Laboratories, Ltd. Company Overview
5.19.1 Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.20 Teva Pharmaceutical Industries Ltd. Company Overview
5.20.1 Teva Pharmaceutical Industries Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.21 University of Kansas Company Overview
5.21.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
5.22 University of Texas Medical Branch at Galveston Company Overview
5.22.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
6 Dry Powder Inhaler Devices- Recent Developments
6.1 Mar 30, 2016: 80 Years of Innovation and Success in Healthcare: Chiesi Reports Significant International Growth in 2015
6.2 Mar 07, 2016: New Health Outcomes Data Reinforce Role of Device Selection and Peak Inspiratory Flow Rate in Treatment of COPD Patients
6.3 Oct 20, 2015: GSK announces positive new data comparing Incruse Ellipta to tiotropium and glycopyrronium in patients with COPD
6.4 Jun 16, 2015: Consort Medical announces final results
7 Appendix
7.1 Methodology
7.2 About us
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables

Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Table 8: Acorda Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 9: CVT-301 Drug Delivery Device - Product Status
Table 10: CVT-301 Drug Delivery Device - Product Description
Table 11: CVT-427 Drug Delivery Device - Product Status
Table 12: CVT-427 Drug Delivery Device - Product Description
Table 13: Adamis Pharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 14: 3M Taper Dry Powder Inhaler - Product Status
Table 15: 3M Taper Dry Powder Inhaler - Product Description
Table 16: APC-5000 - Dry Powder Inhaler - Product Status
Table 17: APC-5000 - Dry Powder Inhaler - Product Description
Table 18: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 19: g60 Dry Powder Inhaler - Product Status
Table 20: g60 Dry Powder Inhaler - Product Description
Table 21: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 22: resQhaler - Product Status
Table 23: resQhaler - Product Description
Table 24: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Fentanyl TAIFUN Inhaler - Product Status
Table 26: Fentanyl TAIFUN Inhaler - Product Description
Table 27: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Ciprofloxacin Dry Powder Inhaler - Product Status
Table 29: Ciprofloxacin Dry Powder Inhaler - Product Description
Table 30: Bespak Europe Ltd. Pipeline Products & Ongoing Clinical Trials Overview
<table>
<thead>
<tr>
<th>Table 62: Dry Powder Inhaler - Product Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 63: Dry Powder Inhaler - Product Description</td>
</tr>
<tr>
<td>Table 64: Sandoz International GmbH Pipeline Products &amp; Ongoing Clinical Trials Overview</td>
</tr>
<tr>
<td>Table 65: Solis Multi-Dose Dry Powder Inhaler - Product Status</td>
</tr>
<tr>
<td>Table 66: Solis Multi-Dose Dry Powder Inhaler - Product Description</td>
</tr>
<tr>
<td>Table 67: Unit-Dose Dry Powder Inhaler - Product Status</td>
</tr>
<tr>
<td>Table 68: Unit-Dose Dry Powder Inhaler - Product Description</td>
</tr>
<tr>
<td>Table 69: Sheffield Hallam University Pipeline Products &amp; Ongoing Clinical Trials Overview</td>
</tr>
<tr>
<td>Table 70: Dry Powder Inhaler - Product Status</td>
</tr>
<tr>
<td>Table 71: Dry Powder Inhaler - Product Description</td>
</tr>
<tr>
<td>Table 72: Shin Nippon Biomedical Laboratories, Ltd. Pipeline Products &amp; Ongoing Clinical Trials Overview</td>
</tr>
<tr>
<td>Table 73: µco System - Product Status</td>
</tr>
<tr>
<td>Table 74: µco System - Product Description</td>
</tr>
<tr>
<td>Table 75: Teva Pharmaceutical Industries Ltd. Pipeline Products &amp; Ongoing Clinical Trials Overview</td>
</tr>
<tr>
<td>Table 76: Spiromax EU / mDPI US - Product Status</td>
</tr>
<tr>
<td>Table 77: Spiromax EU / mDPI US - Product Description</td>
</tr>
<tr>
<td>Table 78: University of Kansas Pipeline Products &amp; Ongoing Clinical Trials Overview</td>
</tr>
<tr>
<td>Table 79: Dry Powder Inhaler - Product Status</td>
</tr>
<tr>
<td>Table 80: Dry Powder Inhaler - Product Description</td>
</tr>
<tr>
<td>Table 81: University of Texas Medical Branch at Galveston Pipeline Products &amp; Ongoing Clinical Trials Overview</td>
</tr>
<tr>
<td>Table 82: Dry Powder Drug Delivery System - Product Status</td>
</tr>
<tr>
<td>Table 83: Dry Powder Drug Delivery System - Product Description</td>
</tr>
<tr>
<td>Table 84: Glossary</td>
</tr>
</tbody>
</table>

1.2 List of Figures

Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016
Web Address: http://www.researchandmarkets.com/reports/3715946/
Office Code: SCPLTKZ9

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:          Mr  ☐  Mrs  ☐  Dr  ☐  Miss  ☐  Ms  ☐  Prof  ☐
First Name: ___________________________________________ Last Name: ________________________________
Email Address: * ________________________________
Job Title: ________________________________
Organisation: ________________________________
Address: __________________________________________
City: __________________________________________
Postal / Zip Code: ________________________________
Country: __________________________________________
Phone Number: __________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World